What is the address of CLEMENT PHARMA?

The registered office of CLEMENT PHARMA is located at Lodewijk de Raetlaan 16 box 2, 8870 Izegem.

Is CLEMENT PHARMA still active?

Yes. According to the CBE (29 October 2026) CLEMENT PHARMA is active, legal situation “Normale toestand”, started on 23 December 1982.

Is CLEMENT PHARMA registered on Peppol?

Yes, CLEMENT PHARMA is registered on the Peppol network with ID 0208:0423344820.

What is the enterprise number of CLEMENT PHARMA?

The enterprise number of CLEMENT PHARMA is BE0423344820.

When was CLEMENT PHARMA founded?

CLEMENT PHARMA was founded on 23 December 1982.

Who are the directors of CLEMENT PHARMA?

According to the 2025 annual accounts, the directors of CLEMENT PHARMA are: 4CC BV, 4 GC SARL naar Luxemburgs recht.

Is CLEMENT PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 December 1982; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CLEMENT PHARMA make in 2025?

CLEMENT PHARMA recorded a loss after taxes of € 160,504 in financial year 2025.

What is the revenue of CLEMENT PHARMA?

As a small company, CLEMENT PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,100,498.

How much does an employee at CLEMENT PHARMA earn?

The average wage cost per full-time employee at CLEMENT PHARMA was € 71,500 in 2025: staff costs of € 1.2 million for 16.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CLEMENT PHARMA have?

According to the 2025 annual accounts, CLEMENT PHARMA has 16.6 full-time equivalents (FTE).

Does CLEMENT PHARMA have a website?

Yes, CLEMENT PHARMA has a website at studioclement.be.

CLEMENT PHARMA (Public Limited) - Izegem - BE0423344820

Q: What does CLEMENT PHARMA do?

CLEMENT PHARMA is registered with the CBE as active in: Groothandel in meubels, niet-elektrische huishoudapparaten en vloerbedekking inclusief tapijten. Public Limited, started on 23 December 1982, 1 establishment.

Dossier CLEMENT PHARMA, printed on 29 October 2026 from databakkes.be/en/0423344820/clement-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CLEMENT PHARMA from Izegem, company number BE0423344820, closed financial year 2025 with a result of € -160,504 after tax. For that financial year CLEMENT PHARMA recorded a gross margin of € 1.1 million and equity of € 860,587. Compared with financial year 2024, the result moved from € 47,328 to € -160,504. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2026.

What it is worth Healthy

€ 860,587

▼ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -160,504

▼ still € 47,328 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 489,028

▲ 223% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 798,587.

People and assets in 2025

Full-time equivalents

16.6

▲ 0.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.2 million

▲ 12% vs 2024

€ 71,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 149,508

▲ 21% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 96,456

▲ 22% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 355,465

▼ 8% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,229,956 Gross margin 2022: € 1,229,956 First fiscal year in the series	€ 1,093,717 Gross margin 2023: € 1,093,717 ▼ 11% vs 2022 (€ 1,229,956) Unfavourable step	€ 1,177,040 Gross margin 2024: € 1,177,040 ▲ 8% vs 2023 (€ 1,093,717) Favourable step	€ 1,100,498 Gross margin 2025: € 1,100,498 ▼ 7% vs 2024 (€ 1,177,040) Unfavourable step	▼ 7%
Profit after taxes	€ 272,214 Profit after taxes 2022: € 272,214 First fiscal year in the series	€ -1,933 Profit after taxes 2023: € -1,933 ▼ € 274,147 vs 2022 (€ 272,214) Unfavourable step	€ 47,328 Profit after taxes 2024: € 47,328 ▲ € 49,261 vs 2023 (€ -1,933) Favourable step	€ -160,504 Profit after taxes 2025: € -160,504 ▼ € 207,832 vs 2024 (€ 47,328) Unfavourable step	▼ € 207,832
Equity	€ 975,696 Equity 2022: € 975,696 First fiscal year in the series	€ 973,763 Equity 2023: € 973,763 Unchanged (€ 975,696) Unfavourable step	€ 1,021,091 Equity 2024: € 1,021,091 ▲ 5% vs 2023 (€ 973,763) Favourable step	€ 860,587 Equity 2025: € 860,587 ▼ 16% vs 2024 (€ 1,021,091) Unfavourable step	▼ 16%
Total debts	€ 530,167 Total debts 2022: € 530,167 First fiscal year in the series	€ 623,937 Total debts 2023: € 623,937 ▲ 18% vs 2022 (€ 530,167) Unfavourable step	€ 466,590 Total debts 2024: € 466,590 ▼ 25% vs 2023 (€ 623,937) Favourable step	€ 451,921 Total debts 2025: € 451,921 ▼ 3% vs 2024 (€ 466,590) Favourable step	▼ 3%
Cash	€ 445,171 Cash 2022: € 445,171 First fiscal year in the series	€ 148,037 Cash 2023: € 148,037 ▼ 67% vs 2022 (€ 445,171) Unfavourable step	€ 151,596 Cash 2024: € 151,596 ▲ 2% vs 2023 (€ 148,037) Favourable step	€ 489,028 Cash 2025: € 489,028 ▲ 223% vs 2024 (€ 151,596) Favourable step	▲ 223%
Retained profit	€ 913,696 Retained profit 2022: € 913,696 First fiscal year in the series	€ 911,763 Retained profit 2023: € 911,763 Unchanged (€ 913,696) Unfavourable step	€ 959,091 Retained profit 2024: € 959,091 ▲ 5% vs 2023 (€ 911,763) Favourable step	€ 798,587 Retained profit 2025: € 798,587 ▼ 17% vs 2024 (€ 959,091) Unfavourable step	▼ 17%
Balance sheet total	€ 1,505,863 Balance sheet total 2022: € 1,505,863 First fiscal year in the series	€ 1,597,700 Balance sheet total 2023: € 1,597,700 ▲ 6% vs 2022 (€ 1,505,863) Unchanged	€ 1,487,681 Balance sheet total 2024: € 1,487,681 ▼ 7% vs 2023 (€ 1,597,700) Unchanged	€ 1,312,507 Balance sheet total 2025: € 1,312,507 ▼ 12% vs 2024 (€ 1,487,681) Unchanged	▼ 12%
Employees (FTE)	13.5 Employees (FTE) 2022: 13.5 First fiscal year in the series	14.9 Employees (FTE) 2023: 14.9 ▲ 1.4 vs 2022 (13.5) Unchanged	15.9 Employees (FTE) 2024: 15.9 ▲ 1 vs 2023 (14.9) Unchanged	16.6 Employees (FTE) 2025: 16.6 ▲ 0.7 vs 2024 (15.9) Unchanged	▲ 0.7

Key figures of CLEMENT PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CLEMENT PHARMA?

What happened at CLEMENT PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 14, 2026 New annual accounts for financial year 2025: loss of € 160,504 (▼ € 207,832 vs 2024). filed late Source: NBB ↗
2025 4 GC SARL naar Luxemburgs recht became a director. NBB
Jan 1, 1983 New establishment in Izegem. KBO
Dec 23, 1982 Start of the company according to the CBE. KBO

In short

From € 272,214 profit in 2022 to € 160,504 loss in 2025.

Paid € 172,000 in corporate taxes since 2022.

Best year ever: 2022, with € 272,214 profit.

On average € 66,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

ECHOFIN 100%

The stake of ECHOFIN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CLEMENT PHARMA

Behind CLEMENT PHARMA are 4CC BV and 4 GC SARL naar Luxemburgs recht. The shares are held by ECHOFIN (100%).

Directors

According to the 2025 annual accounts

4CC BV

Managing director · represented by Els Vandecappelle

Also active at: O.C.I., ECHOFIN, A.C.I., R.C.I., A.C.N.

4 GC SARL naar Luxemburgs recht

Managing director · represented by Jan Clement

Also active at: O.C.I., ECHOFIN, A.C.I.

since 2025

Shareholders

ECHOFIN

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Lodewijk de Raetlaan 16 box 2

8870 Izegem

2.021.531.270

Lodewijk de Raetlaan 16

8870 Izegem

Active since 1 January 1983

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

O.C.I. same network

€ 534,350 gross margin · 2025

ECHOFIN same network

€ 2.3 million revenue · 2025

A.C.I. same network

€ 2 million gross margin · 2025

R.C.I. same network

€ 3 million gross margin · 2025

BTWE OCF

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS studioclement.be

Canonical: https://studioclement.be/nl/

Technologies

Google FontsGoogle Tag ManagerLottieNginxOpenCartPHPWPMLWooCommerceWordPressYoast SEOjQueryjQuery UIlazysizes

Hosting & Email

Email provider

Microsoft 365

Hosting

COMBELL-AS, BE

Website info

HTTPS Ja

Languages NL

Features

Webshop Blog Jobs Ads Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0423.344.820

VAT number

BE 0423.344.820

Registered office

Lodewijk de Raetlaan 16 bus 2, 8870 Izegem

Names & denominations

CLEMENT PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

23 December 1982

Peppol

Active · Active since 9 Dec 2025

Contact

studioclement.be

Activities · NACE

Groothandel in meubels, niet-elektrische huishoudapparaten en vloerbedekking inclusief tapijten

Groothandel in niet-elektrische huishoudelijke artikelen

Vervaardiging van kantoor- en winkelmeubelen

Vervaardiging van kantoor-, winkel- en ateliermeubelen, overwegend van andere materialen dan metaal

Handelsbemiddeling in de groothandel in andere specifieke goederen

Handelsbemiddeling gespecialiseerd in overige goederen, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

CLEMENT PHARMA

Financials

What happened to CLEMENT PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions